Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial
Lists
Only you see this
Abstract
This study provides unique insights into the in vivo contribution of proliferation/cytotoxic CD8+ T cells and inflammation to the Ad26.ZEBOV, MVA-BN-Filo vaccine-induced potency. Clinical Trials Registration. NCT02416453.
BibTeX
@article{lacabaratz2024innate,
author = {Christine Lacabaratz and Mélany Durand and Aurélie Wiedemann and Emile Foucat and Mathieu Surénaud and Corinne Krief and Lydia Guillaumat and Cynthia Robinson and Kerstin Lühn and Viki Bockstal and Rodolphe Thiébaut and Laura Richert and Yves Lévy},
title = {{Innate and Cellular Immune Response to the Ebola Vaccine Ad26.ZEBOV, MVA-BN-Filo: An Ancillary Study of the EBL2001 Phase 2 Trial}},
journal = {The Journal of Infectious Diseases},
year = {2024},
doi = {10.1093/infdis/jiae360},
}Loading related content...